Brigitte Sigal-Zafrani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Brigitte Sigal-Zafrani has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Alain Fourquet
Department of Radiotherapy, Institut Curie, Paris, France
3 shared publications - Anne Vincent-Salomon
Institut Curie, PSL University
3 shared publications - Xavier Sastre-Garau
Department of Biopathology, Institut Curie, Paris, France
3 shared publications Krishna B Clough
2 shared publications- Patricia de Cremoux
Department of Molecular Biology
2 shared publications - Remi Dendale
Institut Curie, Paris-Orsay, France
2 shared publications
Latest Publications
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 550
Systematic biopsy of the first metastatic event in breast cancer: Results from ESOPE—A prospective multicenter trial.
550 Background: Tumoral heterogeneity and systemic therapies may induce marked biological differences between the primary tumor (PT) and metastatic (M) tissue in breast cancer (BC). Clinical utility of m biopsy has not been demonstrated. We conducted a prospective study comparing the subtype and the molecular profile of PT and the matched first m event. Methods: ESOPE (NCT 01956552) is a prospective, multicenter trial conducted between 11/2010 and 09/2013. Main inclusion criteria were: patients with available formalin-fixed paraffin-embedded (FFPE) PT sample, and presenting with a first m event accessible to sampling. No previous therapy for m disease was allowed. FFPE tissue samples from PT and m were locally and centrally analyzed for ER, PgR, Ki67 and HER2. Impact on therapeutic decision and clinical outcome were recorded. Comparative genomic analyses including targeted sequencing, exome sequencing and RNAseq were preplanned on FFPE and frozen samples. Results: Overall, 130 pts were included. Median age was 57y (28-81). Median delay to m was 42 m (0-270), 75 pts (61%) had 2+ m sites. Most frequent sites were liver (60%), lymph nodes (44%), bone (43%) and lung/pleura (34%). A biopsy was feasible and performed in 117 pts (90%). After a median delay of 20.7 days, most frequently biopsied sites were liver (45%), lymph node (13%), bone (11%) and lung (10%). A second non BC cancer or benign disease was observed in 5 and 1 pt. Ultimately, 84 matched PT/M pairs were centrally reviewed. PT/M subtype concordance was 100% for triple negative (n = 16) tumors. HER2 (n = 16), lum B PT (n = 29) and lum A PT (n = 23) changed of phenotype in 4%, 20% and 52% of cases, respectively. Treatment allocation was determined according to results of the biopsy in 26.2% of patients with matched PT/M. Overall survival was highly correlated with the m subtype: median OS was 15m (triple negative), 34m (Lum B), 41m (HER2) and not reached (Lum A) (p = 0.0002). Conclusions: Metastatic subtype differs from the PT in BC mostly in Lum A tumors. Systematic m biopsy at the first event yields a treatment change in almost 25% of the patients, underlining its clinical utility. Ongoing in depth genomic analyses will illustrate specific biological changes in m tissue. Clinical trial information: NCT01956552.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 550
Systematic biopsy of the first metastatic event in breast cancer: Results from ESOPE—A prospective multicenter trial.
550 Background: Tumoral heterogeneity and systemic therapies may induce marked biological differences between the primary tumor (PT) and metastatic (M) tissue in breast cancer (BC). Clinical utility of m biopsy has not been demonstrated. We conducted a prospective study comparing the subtype and the molecular profile of PT and the matched first m event. Methods: ESOPE (NCT 01956552) is a prospective, multicenter trial conducted between 11/2010 and 09/2013. Main inclusion criteria were: patients with available formalin-fixed paraffin-embedded (FFPE) PT sample, and presenting with a first m event accessible to sampling. No previous therapy for m disease was allowed. FFPE tissue samples from PT and m were locally and centrally analyzed for ER, PgR, Ki67 and HER2. Impact on therapeutic decision and clinical outcome were recorded. Comparative genomic analyses including targeted sequencing, exome sequencing and RNAseq were preplanned on FFPE and frozen samples. Results: Overall, 130 pts were included. Median age was 57y (28-81). Median delay to m was 42 m (0-270), 75 pts (61%) had 2+ m sites. Most frequent sites were liver (60%), lymph nodes (44%), bone (43%) and lung/pleura (34%). A biopsy was feasible and performed in 117 pts (90%). After a median delay of 20.7 days, most frequently biopsied sites were liver (45%), lymph node (13%), bone (11%) and lung (10%). A second non BC cancer or benign disease was observed in 5 and 1 pt. Ultimately, 84 matched PT/M pairs were centrally reviewed. PT/M subtype concordance was 100% for triple negative (n = 16) tumors. HER2 (n = 16), lum B PT (n = 29) and lum A PT (n = 23) changed of phenotype in 4%, 20% and 52% of cases, respectively. Treatment allocation was determined according to results of the biopsy in 26.2% of patients with matched PT/M. Overall survival was highly correlated with the m subtype: median OS was 15m (triple negative), 34m (Lum B), 41m (HER2) and not reached (Lum A) (p = 0.0002). Conclusions: Metastatic subtype differs from the PT in BC mostly in Lum A tumors. Systematic m biopsy at the first event yields a treatment change in almost 25% of the patients, underlining its clinical utility. Ongoing in depth genomic analyses will illustrate specific biological changes in m tissue. Clinical trial information: NCT01956552.
- 1 May 2009
- Vol. 29 (5) , 1475-82
Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
This retrospective analysis was designed to confirm the predictive role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) in the outcome of early stage, node-negative breast cancer patients. Node-negative patients having not received adjuvant chemotherapy, and for whom frozen samples were available, were selected. Among the 169 patients included, 56.8% presented with uPA >3 ng/mg of proteins and/or PAI-1 >14 ng/mg of proteins. The median follow-up was 73 months. Significant correlations were found between uPA and disease-free survival (p [univariate]=0.003; p [multivariate]=0.01), and between uPA, PAI-1, and uPA plus PAI-1 and distant relapses (p=0.002). No significant correlation was found between uPA/PAI-1 and the risk of locoregional recurrence. This study demonstrated that uPA and PAI-1 are useful predictors of distant metastases in a subset of early stage, node-negative breast cancer patients.
- 1 May 2009
- Vol. 29 (5) , 1475-82
Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
This retrospective analysis was designed to confirm the predictive role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) in the outcome of early stage, node-negative breast cancer patients. Node-negative patients having not received adjuvant chemotherapy, and for whom frozen samples were available, were selected. Among the 169 patients included, 56.8% presented with uPA >3 ng/mg of proteins and/or PAI-1 >14 ng/mg of proteins. The median follow-up was 73 months. Significant correlations were found between uPA and disease-free survival (p [univariate]=0.003; p [multivariate]=0.01), and between uPA, PAI-1, and uPA plus PAI-1 and distant relapses (p=0.002). No significant correlation was found between uPA/PAI-1 and the risk of locoregional recurrence. This study demonstrated that uPA and PAI-1 are useful predictors of distant metastases in a subset of early stage, node-negative breast cancer patients.
- Open Access
- 6 April 2007
- Published by Springer Nature in Breast Cancer Research
- Vol. 9 (2) , R24
Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity
Introduction: Typical medullary breast carcinoma (MBC) has recently been recognized to be part of the basal-like carcinoma spectrum, a feature in agreement with the high rate of TP53 mutations previously reported in MBCs. The present study was therefore designed to identify phenotypic and genetic alterations that distinguish MBCs from basal-like carcinomas (BLC). Methods: Expression levels of estrogen receptor (ER), progesterone receptor (PR), ERBB2, TP53, cytokeratins (KRTs) 5/6, 14, 8/18, epidermal growth factor receptor and KIT, as well as TP53 gene sequence and high-density array comparative genomic hybridization (CGH) profiles, were assessed and compared in a series of 33 MBCs and 26 BLCs. Results: All tumors were negative for ER, PR and ERBB2. KRTs 5/6 were more frequently expressed in MBCs (94%) than in BLCs (56%) (p = 0.0004). TP53 mutations were disclosed in 20/26 MBCs (77%) and 20/24 BLCs (83%). Array CGH analysis showed that a higher number of gains (95 regions) and losses (34 regions) was observed in MBCs than in BLCs (36 regions of gain; 13 regions of losses). In addition, gains of 1q and 8q, and losses of X were found to be common to the two groups, whereas gains of 10p (53% of the cases), 9p (30.8% of the cases) and 16q (25.8% of the cases), and losses of 4p (34.8% of the cases), and amplicons of 1q, 8p, 10p and 12p were the genetic alterations found to characterize MBC. Conclusion: Our study has revealed that MBCs are part of the basal-like group and share common genomic alterations with BLCs, the most frequent being 1q and 8q gains and X losses; however, MBCs are a distinct entity within the basal-like spectrum, characterized by a higher rate of KRT 5/6 expression, a higher rate of gains and losses than BLCs, recurrent 10p, 9p and 16q gains, 4p losses, and 1q, 8p, 10p and 12p amplicons. Our results thus contribute to a better understanding of the heterogeneity in basal-like breast tumors and provide potential diagnostic tools.
- 6 April 2007
- Published by Springer Nature in Breast Cancer Research
- Vol. 9 (2) , R24
Open AccessIdentification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity
Introduction: Typical medullary breast carcinoma (MBC) has recently been recognized to be part of the basal-like carcinoma spectrum, a feature in agreement with the high rate of TP53 mutations previously reported in MBCs. The present study was therefore designed to identify phenotypic and genetic alterations that distinguish MBCs from basal-like carcinomas (BLC). Methods: Expression levels of estrogen receptor (ER), progesterone receptor (PR), ERBB2, TP53, cytokeratins (KRTs) 5/6, 14, 8/18, epidermal growth factor receptor and KIT, as well as TP53 gene sequence and high-density array comparative genomic hybridization (CGH) profiles, were assessed and compared in a series of 33 MBCs and 26 BLCs. Results: All tumors were negative for ER, PR and ERBB2. KRTs 5/6 were more frequently expressed in MBCs (94%) than in BLCs (56%) (p = 0.0004). TP53 mutations were disclosed in 20/26 MBCs (77%) and 20/24 BLCs (83%). Array CGH analysis showed that a higher number of gains (95 regions) and losses (34 regions) was observed in MBCs than in BLCs (36 regions of gain; 13 regions of losses). In addition, gains of 1q and 8q, and losses of X were found to be common to the two groups, whereas gains of 10p (53% of the cases), 9p (30.8% of the cases) and 16q (25.8% of the cases), and losses of 4p (34.8% of the cases), and amplicons of 1q, 8p, 10p and 12p were the genetic alterations found to characterize MBC. Conclusion: Our study has revealed that MBCs are part of the basal-like group and share common genomic alterations with BLCs, the most frequent being 1q and 8q gains and X losses; however, MBCs are a distinct entity within the basal-like spectrum, characterized by a higher rate of KRT 5/6 expression, a higher rate of gains and losses than BLCs, recurrent 10p, 9p and 16q gains, 4p losses, and 1q, 8p, 10p and 12p amplicons. Our results thus contribute to a better understanding of the heterogeneity in basal-like breast tumors and provide potential diagnostic tools.
- 24 September 2004
- Vol. 91, 641-7
[Routine sentinel node detection in breast cancer. Experience of the Curie Institute].
Since January 2000, sentinel lymph node detection is routinely performed at the Institut Curie, involving a multidisciplinary team of trained surgeons, nuclear medicine physicians, radiologists and pathologists. During a three-year period, 738 patients undergoing tumorectomy with conservative surgical treatment of the breast were included in the sentinel node procedure consisting of systematic pre-operative tumor biopsies, peritumoral lymph tracer injections at tumor contact (radionuclide/blue dye), primary surgical removal of the first sentinel lymph node, frozen section diagnosis, followed by a standardized pathological analysis, and finally the application of precise criteria to determine whether further surgery is necessary. This article is an evaluation of the sentinel lymph node technique in a specialized Center providing a breakdown of the strong points and weak points of the procedure.
- 24 September 2004
- Vol. 91, 641-7
[Routine sentinel node detection in breast cancer. Experience of the Curie Institute].
Since January 2000, sentinel lymph node detection is routinely performed at the Institut Curie, involving a multidisciplinary team of trained surgeons, nuclear medicine physicians, radiologists and pathologists. During a three-year period, 738 patients undergoing tumorectomy with conservative surgical treatment of the breast were included in the sentinel node procedure consisting of systematic pre-operative tumor biopsies, peritumoral lymph tracer injections at tumor contact (radionuclide/blue dye), primary surgical removal of the first sentinel lymph node, frozen section diagnosis, followed by a standardized pathological analysis, and finally the application of precise criteria to determine whether further surgery is necessary. This article is an evaluation of the sentinel lymph node technique in a specialized Center providing a breakdown of the strong points and weak points of the procedure.
- 1 January 2004
- Published by Elsevier in Laboratory Investigation
- Vol. 17 (1) , 81-88
Histological margin assessment for breast ductal carcinoma in situ: precision and implications
- 1 January 2004
- Published by Elsevier in Laboratory Investigation
- Vol. 17 (1) , 81-88
Histological margin assessment for breast ductal carcinoma in situ: precision and implications